ABSTRACT
MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies have shown promise in decreasing mortality in ARDS and suggest benefits in treatment of COVID-19 related ARDS. We performed a meta-analysis of published trials assessing the effectiveness and adverse events (AE) of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through April 8th, 2021. Reports in all languages including randomized clinical trials (RCTs), comparative observational studies, and case series/case reports were included. Random effects model was used to pool outcomes from RCTs and comparative observational studies. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory and imaging findings. A total of 413 patients were identified from 25 studies, which included 8 controlled trials (3 RCTs), 5 comparative observational studies, (n=300) and 17 case-series/case reports (n=113). The patients age was 60.5 years (mean), 33.7% were women. When compared with the control group, MSC cell therapy was associated with reduction in all-cause mortality (RR=0.31, 95% CI: 0.12 to 0.75, I2=0.0%; 3 RCTs and 5 comparative observational studies, 300 patients), reduction in SAEs (IRR=0.36, 95% CI: 0.14 to 0.90, I2=0.0%; 3 RCTs and 2 comparative studies, n=219), no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared to conventional care. Large scale double-blinded, well-powered RCTs should be conducted to further explore these results.
Competing Interest Statement
W. Q.; J. M. H.; J. K.; C. R. reported roles as principal investigators of MSC trials. J. M. H. reported having a patent for cardiac cell‐based therapy holds equity in Vestion Inc. and maintains a professional relationship with Vestion Inc. as a consultant and member of the Board of Directors and Scientific Advisory Board; J. M. H. is also the Chief Scientific Officer a compensated consultant and advisory board member for Longeveron and holds equity in Longeveron; J. M. H. is the coinventor of intellectual property licensed to Longeveron. J. M. H. declared inventor or patent holder and research funding from Longeron; Heart Genomics; advisory role and research funding with Vestion; research funding from NHLBI. J. K. declare Intellectual property rights with IDF; hCT‐MSC for treatment of ASD HIE which were licensed to CryoCell Int l by Duke University; NMDP Scientific Advisor; Celularity SAB; research funding from the Marcus Foundation NIH HRSA; leadership position with Istari CMO (spouse). G. B. consults for SciNeuro and Vida Ventures, had consulted for AbbVie E-Scape and Eisai and receives funding from NIH and Cure Alzheimers Fund. He serves as a Co Editor in Chief for Molecular Neurodegeneration. The other authors indicated no potential conflicts of interest. K.M. is a consultant in RESTEM.
Funding Statement
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Appropriate institutional review board (IRB) review and approval should accompany all studies involving human participants or research material derived from human participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data analyzed in this study were a re-analysis of existing data, which are openly available at locations cited in the reference section.
